Short-TermMedium-TermLong-TermSignals

Phibro Animal Health [PAHC]

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers Specialty Generic
Last Updated 24 Jun 2026 @ 10:33 (Exchange is open)
Last: $31.81 4.19%
-2.86
GaG Algo Score™
v1.0
Short
-2.86
Medium
-3.38
Long
-3.06

Stats

Today's Volume 30 275
Average Volume 360 667
Market Cap 1.24B
EPS $0.590 (Q3 | 2026-05-06)
Next earnings date ($0.723) 2026-09-02
Last Dividend $0.120 (2026-06-03)
P/E 10.86 (Sector) 26.21 (Industry) N/A
ATR14 $1.495 (4.90%)
Possible DaySwing $29.78 - $31.28 (5.02%)

Support and Resistance Levels

Line

Pivot Data

Pivot Statistics
Metric Average Median Std Dev
Gain % 13.64% 13.64% 3.13%
Loss % -51.25% -51.25% 0.00%
Duration 12.0d 7d 13.2d
Total Pivots Found 4
Gain/Loss Legs 3 (2 Gain / 1 Loss)
Last Pivot Top @ $33.04 on 2026-06-04
Change since Last Pivot $-2.51 (-7.60%)
Next Pivot Prediction Last: $31.81
Predicted Next Type Bottom
Predicted Price (Avg) $16.11
Predicted Price (Median) $16.11
Predicted Price Range (~68%) $16.11 - $16.11
Change to Avg Target $-15.70 (-49.36%)
Predicted Date (Avg) 2026-06-16
Predicted Date Range (~68%) 2026-06-02 - 2026-06-29
Basis Based on 1 historical losses (Avg: -51.25%, Median: -51.25%, StdDev of Abs: 0.00%) and duration (Avg: 12.0 days, StdDev: 13.2 days)
Note Ranges assume ~normal distribution & historical patterns repeat. Use with caution.

Moderate loss for Phibro Animal Health on Tuesday.

Phibro Animal Health (PAHC) stock price suffered a considerable decline on Tuesday after the stock fell $-0.540 (-1.74%) from the previous session on normal volume. The stock slightly underperformed the market, lagging slightly behind the NASDAQ's 0.22% rise. Yesterday's trading volume was 198 239 shares, worth about $6.05M. This represents 51 900 shares less than the day before. Volume was below the 10-day average of 263 753 shares.

Phibro Animal Health signals

There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-33.3%), medium- (-33.3%), and long-term (-33.3%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.

Phibro Animal Health Support & Resistance Levels

The stock is trading above the closest support level at $29.90. approximately $0.630 (2.06%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support s129.9 -

Phibro Animal Health Evaluation

  • Short score: -2.86
  • Medium score: -3.38
  • Long score: -3.06

Ownership flow

GetAGraph InsiderPower

2.56
Transactions 144
Buy power 756 493
Sell power 693 256
2026-05-29 Corcoran E Thomas Buy
2026-05-07 Bendheim Jack Sell
2026-05-07 Bendheim Jack Sell
2026-05-07 Bendheim Jack Sell
2026-05-07 Bendheim Jack Sell

Positioning pressure

Short interest pressure

Normal
Short interest 2.72% Of outstanding shares
Short float 2.74% Of tradable float
Days to cover 3.08 Short interest divided by average volume
Squeeze probability 1.90% -6.54% change

Short positioning does not currently stand out as a dominant risk factor.

Updated 2026-05-29

Income profile

Dividend profile

Score 2.89
Last Dividend $0.120 2026-06-03
Next Dividend $0 N/A
Avg. yearly yield 2.27% Quarterly
Total paid $5.42 48 payments
Sustainability 0 low (50.00%)
Growth potential 5.00 Stable (0.00%)
Direction 0 Score based on dividend trend and payout behavior.

Yearly history

Year Dividend Yield
- $0.240 0.64%
- $0.480 2.32%
- $0.480 4.06%
- $0.480 3.51%
- $0.480 2.30%
- $0.480 2.44%

Recent payments

Date Dividend Payment
2026-06-03 $0.120 2026-06-24
2026-03-04 $0.120 2026-03-25
2025-11-26 $0.120 2025-12-17
2025-09-03 $0.120 2025-09-24
2025-06-04 $0.120 2025-06-25

Earnings quality

Earnings history

Latest surprise 21.15%
Reported quarters 11
EPS beats 7
EPS misses 3
Avg. surprise 10.62%
Q2/2024
Q3/2024
Q4/2024
Q1/2025
Q2/2025
Q3/2025
Q4/2025
Q1/2026
Period Date Actual EPS Estimate Surprise Revenue
Q1/2026 2025-11-04 $0.650 - - 363.89M
Q4/2025 2025-08-27 - $0.520 - -
Q3/2025 2025-05-07 $0.630 $0.520 21.15% 347.83M
Q2/2025 2025-02-05 $0.540 $0.400 35.00% 309.26M
Q1/2025 2024-11-07 $0.350 $0.250 40.00% 260.43M
Q4/2024 2024-08-28 $0.410 $0.340 20.59% 273.16M
Q3/2024 2024-05-08 $0.310 $0.290 6.90% 263.22M
Q2/2024 2024-02-07 $0.330 $0.270 22.22% 249.94M

Analyst view

Analyst targets

<i class="arrow arrow-up"></i>54.04%
Consensus $49.00
Median $49.00
Low $49.00
High $49.00

Recent target updates

$49.00 Morgan Stanley
Feb 6, 2026
Open
$34.00 Morgan Stanley
Aug 28, 2025
Open
$26.00 Morgan Stanley
Jun 25, 2025
Open
$20.00 Morgan Stanley
Erin Wright Apr 15, 2025
Open
$18.00 Roth Capital
Dec 21, 2022
Open
$17.00 Barclays
Sep 16, 2022
Open

News flow

Latest company news

Company context

Company profile

Website
Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers Specialty Generic
Currency USD

Phibro Animal Health Corporation operates as a global entity focused on the research production and supply of a wide array of animal health and mineral nutrition solutions While serving a global clientele its primary market for livestock products is the United States The companys operations are divided into three main business segments Animal Health Mineral Nutrition and Performance Products Phibro develops manufactures and markets products tailored for various foodproducing animals including poultry swine beef and dairy cattle and aquaculture Its Animal Health offerings encompass a broad range of pharmaceutical and biological products These include antimicrobials both chemical and biological agents designed to prevent and treat bacterial ailments anticoccidials primarily used to control and prevent coccidiosis in poultry and cattle anthelmintics for combating parasitic intestinal worm infestations and specific antibloat treatments for cattle grazing on legume or wheat pastures Additionally the company provides specialized nutritional supplements engineered to enhance animal health and performance alongside vaccines predominantly for the poultry and swine industries to protect against diseases The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates featuring elements such as zinc manganese copper iron and other vital compounds Furthermore under its Performance Products segment Phibro supplies an assortment of specialty ingredients that find application in diverse industries including personal care industrial chemicals and chemical catalysts Phibros animal health and mineral nutrition products reach customers through a multichannel distribution network including its own local sales offices direct sales to integrated poultry swine and cattle operations and through commercial animal feed producers wholesalers and distributors The company boasts an extensive international presence conducting business across the United States Latin America Canada Europe the Middle East Africa and the Asia Pacific region Initially known as Philipp Brothers Chemicals Inc the company adopted the name Phibro Animal Health Corporation in July 2003 It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck New Jersey